



Belgian Cancer Registry



Cancer Fact Sheet

# Myeloid Malignancies

**Belgium 2018**

1. Cancer Incidence

1.1. Number of new diagnoses and incidence rates

**Table 1:** Myeloid Malignancies: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence rates (ESR and WSR) and cumulative risk by sex and region, 2018

| Males                   | Age (years) | N     | CR   | ESR  | WSR  | CRi  |
|-------------------------|-------------|-------|------|------|------|------|
| Belgium                 | 69.8        | 1,388 | 24.8 | 17.6 | 11.9 | 1.26 |
| Brussels-Capital Region | 67.3        | 120   | 20.5 | 19.9 | 13.5 | 1.45 |
| Flemish Region          | 69.8        | 799   | 24.7 | 16.4 | 11.2 | 1.17 |
| Walloon Region          | 70.4        | 469   | 26.5 | 19.5 | 12.9 | 1.40 |


| Females                 | Age (years) | N     | CR   | ESR  | WSR  | CRi  |
|-------------------------|-------------|-------|------|------|------|------|
| Belgium                 | 69.3        | 1,242 | 21.5 | 13.7 | 9.8  | 1.06 |
| Brussels-Capital Region | 68.7        | 125   | 20.4 | 16.0 | 11.1 | 1.21 |
| Flemish Region          | 69.3        | 659   | 19.9 | 12.3 | 8.9  | 0.94 |
| Walloon Region          | 69.5        | 458   | 24.7 | 15.8 | 11.2 | 1.25 |

CR=Crude (all ages) Rate (N/100,000 person-years)  
ESR=Age-Standardised Rate, using the European Standard Population (N/100,000 person-years)  
WSR=Age-Standardised Rate, using the World Standard Population (N/100,000 person-years)  
CRi=Cumulative Risk for 0-74 years (%)

Belgian Cancer Registry



**Figure 1:** Myeloid Malignancies: Age-standardised incidence rates by sex and region, 2018




1.2. Age-specific incidence rates

**Table 2:** Myeloid Malignancies: Age-specific incidence rates, crude rate (CR) and age-standardised incidence rates (ESR and WSR) by sex, Belgium 2018

|         | 00- | 05- | 10- | 15- | 20- | 25- | 30- | 35- | 40- | 45-  | 50-  | 55-  | 60-  | 65-  | 70-  | 75-   | 80-   | 85+   | CR   | ESR  | WSR  |
|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|------|------|-------|-------|-------|------|------|------|
| Males   | 0.6 | 0.6 | 1.8 | 1.9 | 2.1 | 2.2 | 3.3 | 5.1 | 4.9 | 7.3  | 17.1 | 24.6 | 37.3 | 57.6 | 88.2 | 138.8 | 151.2 | 173.1 | 24.8 | 17.6 | 11.9 |
| Females | 1.3 | 0.6 | 1.3 | 1.0 | 2.4 | 4.0 | 1.9 | 7.2 | 6.9 | 12.4 | 14.2 | 18.1 | 33.9 | 45.0 | 63.2 | 86.3  | 92.0  | 86.2  | 21.5 | 13.7 | 9.8  |

CR=Crude (all ages) Rate (N/100,000 person-years)  
ESR=Age-Standardised Rate, using the European Standard Population (N/100,000 person-years)  
WSR=Age-Standardised Rate, using the World Standard Population (N/100,000 person-years)

**Figure 2:** Myeloid Malignancies: Age-specific incidence rates by sex, 2014-2018



1.3. Trends in incidence


**Table 3:** Myeloid Malignancies: Age-standardised incidence rates (WSR) and average annual percentage change (AAPC) by incidence year, sex and region

| Males                   | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | AAPC | 95% CI     |
|-------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------------|
| Belgium                 | 8.9  | 9.0  | 8.3  | 9.0  | 9.9  | 10.1 | 10.7 | 11.7 | 11.2 | 11.4 | 12.3 | 12.1 | 12.4 | 12.4 | 11.9 | 2.9  | [2.3; 3.5] |
| Brussels-Capital Region | 8.6  | 8.1  | 7.0  | 7.3  | 9.1  | 11.0 | 9.2  | 12.4 | 12.9 | 12.6 | 11.8 | 12.0 | 12.8 | 12.8 | 13.5 | 4.5  | [3.0; 6.1] |
| Flemish Region          | 9.0  | 9.6  | 8.9  | 9.5  | 10.3 | 9.7  | 10.9 | 11.1 | 10.1 | 10.3 | 11.9 | 11.5 | 12.2 | 11.5 | 11.2 | 2.0  | [1.3; 2.6] |
| Walloon Region          | 8.6  | 8.2  | 7.3  | 8.3  | 9.2  | 10.5 | 10.7 | 12.6 | 13.1 | 13.3 | 13.2 | 13.4 | 12.6 | 13.9 | 12.9 | 3.0  | [2.4; 3.6] |

| Females                 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | AAPC | 95% CI     |
|-------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------------|
| Belgium                 | 6.0  | 6.7  | 6.1  | 7.0  | 7.0  | 6.8  | 7.7  | 7.9  | 8.4  | 9.0  | 8.8  | 8.7  | 9.0  | 9.3  | 9.8  | 3.4  | [2.9; 4.0] |
| Brussels-Capital Region | 6.3  | 6.9  | 4.9  | 7.2  | 7.6  | 5.6  | 7.2  | 8.6  | 7.8  | 10.6 | 8.3  | 7.5  | 9.2  | 10.4 | 11.1 | 4.2  | [2.3; 6.1] |
| Flemish Region          | 6.3  | 7.2  | 6.0  | 7.6  | 7.3  | 7.1  | 7.9  | 7.6  | 7.9  | 8.2  | 8.1  | 8.3  | 8.4  | 8.6  | 8.9  | 2.2  | [1.5; 3.0] |
| Walloon Region          | 5.4  | 5.8  | 6.6  | 6.0  | 6.4  | 6.6  | 7.6  | 8.4  | 9.4  | 10.0 | 10.1 | 9.6  | 10.2 | 10.1 | 11.2 | 4.7  | [4.0; 5.4] |

WSR=Age-Standardised Rate, using the World Standard Population (N/100,000 person-years)  
AAPC = Average Annual Percentage Change over the 2004-2018 period

**Figure 3:** Myeloid Malignancies: Age-standardised incidence rates (WSR) by incidence year, sex and region




1.4. Incidence by broad age groups

**Table 4:** Myeloid Malignancies: Number of new diagnoses and age-standardised incidence rates (WSR) by broad age groups and incidence year by sex, Belgium

|          | N    |       |       |       |       |       |       |       |       |       | WSR   |       |       |       |       |       |       |       |       |       |
|----------|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|          | 2009 | 2010  | 2011  | 2012  | 2013  | 2014  | 2015  | 2016  | 2017  | 2018  | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | 2015  | 2016  | 2017  | 2018  |
| Males    |      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| All ages | 970  | 1,060 | 1,180 | 1,149 | 1,237 | 1,308 | 1,340 | 1,340 | 1,391 | 1,388 | 10.1  | 10.7  | 11.7  | 11.2  | 11.4  | 12.3  | 12.1  | 12.4  | 12.4  | 11.9  |
| 0-14 y   | 10   | 11    | 14    | 10    | 9     | 12    | 13    | 15    | 13    | 10    | 1.1   | 1.2   | 1.5   | 1.1   | 0.9   | 1.3   | 1.3   | 1.5   | 1.5   | 1.0   |
| 15-44 y  | 81   | 91    | 79    | 89    | 61    | 85    | 80    | 85    | 83    | 70    | 3.4   | 4.0   | 3.3   | 3.8   | 2.5   | 3.7   | 3.3   | 3.7   | 3.6   | 3.0   |
| 45-54 y  | 79   | 83    | 102   | 97    | 101   | 108   | 96    | 108   | 103   | 99    | 10.1  | 10.3  | 12.6  | 11.8  | 12.2  | 13.0  | 11.5  | 13.1  | 12.3  | 11.8  |
| 55-64 y  | 170  | 158   | 212   | 182   | 197   | 217   | 201   | 214   | 223   | 224   | 26.7  | 24.4  | 32.0  | 27.2  | 29.4  | 31.9  | 29.3  | 30.9  | 31.2  | 30.9  |
| 65-74 y  | 259  | 272   | 283   | 294   | 324   | 334   | 358   | 376   | 387   | 382   | 59.3  | 61.0  | 64.1  | 64.6  | 69.4  | 70.1  | 73.4  | 74.7  | 73.1  | 69.8  |
| 75+ y    | 371  | 445   | 490   | 477   | 545   | 552   | 592   | 542   | 582   | 603   | 105.8 | 125.1 | 134.8 | 128.4 | 146.3 | 141.9 | 149.4 | 136.0 | 143.3 | 150.5 |
| Females  |      |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| All ages | 751  | 861   | 923   | 1,006 | 1,052 | 1,114 | 1,093 | 1,147 | 1,150 | 1,242 | 6.8   | 7.7   | 7.9   | 8.4   | 9.0   | 8.8   | 8.7   | 9.0   | 9.3   | 9.8   |
| 0-14 y   | 8    | 17    | 7     | 17    | 18    | 7     | 12    | 17    | 11    | 10    | 0.9   | 2.0   | 0.8   | 1.9   | 2.0   | 0.8   | 1.3   | 1.8   | 1.2   | 1.1   |
| 15-44 y  | 73   | 76    | 80    | 66    | 83    | 82    | 78    | 72    | 93    | 85    | 3.1   | 3.2   | 3.5   | 2.8   | 3.5   | 3.6   | 3.5   | 3.0   | 4.1   | 3.7   |
| 45-54 y  | 75   | 90    | 86    | 113   | 85    | 82    | 88    | 84    | 83    | 105   | 9.4   | 11.4  | 10.7  | 13.9  | 10.6  | 10.3  | 11.1  | 10.6  | 10.6  | 13.2  |
| 55-64 y  | 118  | 111   | 137   | 140   | 146   | 160   | 151   | 163   | 174   | 191   | 18.2  | 16.8  | 20.2  | 20.3  | 21.2  | 23.0  | 21.3  | 22.7  | 24.0  | 26.0  |
| 65-74 y  | 173  | 192   | 208   | 202   | 267   | 246   | 239   | 278   | 286   | 313   | 33.6  | 37.6  | 41.1  | 38.8  | 51.0  | 46.2  | 44.0  | 50.0  | 49.1  | 52.3  |
| 75+ y    | 304  | 375   | 405   | 468   | 453   | 537   | 525   | 533   | 503   | 538   | 52.5  | 63.5  | 67.1  | 74.8  | 73.6  | 86.4  | 82.1  | 85.0  | 80.5  | 87.7  |

N=Number of invasive tumours  
WSR=Age-Standardised Rate, using the World Standard Population (N/100,000 person-years)

**Figure 4:** Myeloid Malignancies: Age-standardised incidence rates (WSR) versus incidence year by broad age groups for males (top) and females (bottom), Belgium




2. Relative survival


**Table 5:** Myeloid Malignancies: 5-year relative survival proportion by sex, age group and region, Belgium 2014-2018

|                         | 5-year relative survival 2014-2018 (%) |          |              |           |          |              |
|-------------------------|----------------------------------------|----------|--------------|-----------|----------|--------------|
|                         | Males                                  |          |              | Females   |          |              |
|                         | N at risk                              | estimate | 95% CI       | N at risk | estimate | 95% CI       |
| Overall                 | 6,678                                  | 53.8     | [52.0, 55.7] | 5,662     | 60.6     | [58.8, 62.6] |
| Age group               |                                        |          |              |           |          |              |
| 15-59 years             | 1,342                                  | 79.5     | [76.8, 82.0] | 1,197     | 77.4     | [74.6, 80.1] |
| 60-74 years             | 2,477                                  | 55.3     | [52.5, 58.2] | 1,840     | 64.3     | [61.4, 67.2] |
| 75+ years               | 2,860                                  | 37.4     | [34.2, 40.8] | 2,625     | 48.4     | [45.0, 52.0] |
| Region                  |                                        |          |              |           |          |              |
| Brussels-Capital Region | 522                                    | 55.1     | [48.6, 61.4] | 502       | 58.3     | [51.1, 65.2] |
| Flemish Region          | 3,953                                  | 53.1     | [50.8, 55.6] | 3,120     | 61.6     | [59.1, 64.2] |
| Walloon Region          | 2,203                                  | 54.6     | [51.5, 57.9] | 2,040     | 59.6     | [56.4, 62.8] |


**Figure 5:** Myeloid Malignancies: relative survival proportion by sex, Belgium 2014-2018




**Figure 6:** Myeloid Malignancies: relative survival proportion by age group in males, Belgium 2014-2018



**Figure 7:** Myeloid Malignancies: relative survival proportion by age group in females, Belgium 2014-2018



**Figure 8:** Myeloid Malignancies: relative survival proportion by region in males, Belgium 2014-2018



**Figure 9:** Myeloid Malignancies: relative survival proportion by region in females, Belgium 2014-2018

